Amarin Corp Plcuk AMRN
We take great care to ensure that the data presented and summarized in this overview for AMARIN CORP PLCUK is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMRN
View all-
Sarissa Capital Management LP Greenwich, CT24.9MShares$267 Million3.7% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12.4MShares$134 Million0.38% of portfolio
-
Morgan Stanley New York, NY4.41MShares$47.4 Million0.0% of portfolio
-
Waterfront Wealth Inc.2.51MShares$27.1 Million5.52% of portfolio
-
Scp Investment, LP2.5MShares$26.9 Million1.0% of portfolio
-
Two Sigma Investments, LP New York, NY2.17MShares$23.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.79MShares$19.2 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny1.74MShares$18.7 Million0.0% of portfolio
-
Longitude (Cayman) Ltd. Grand Cayman, E91.62MShares$17.4 Million1.11% of portfolio
-
Eversept Partners, LP New York, NY1.52MShares$16.3 Million0.07% of portfolio
Latest Institutional Activity in AMRN
Top Purchases
Top Sells
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Transactions at AMRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 18
2025
|
Mark Di Paolo |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Mark Di Paolo |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Patrice Eadon Bonfiglio |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Patrice Eadon Bonfiglio |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Oliver O'Connor |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Oliver O'Connor |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Louis Sterling Iii |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-10.79%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Louis Sterling Iii |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+17.14%
|
-
|
|
Apr 18
2025
|
Diane E. Sullivan |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Diane E. Sullivan |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Kostas D Odysseas |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Kostas D Odysseas |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Keith Horn |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Keith Horn |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 18
2025
|
Paul Cohen |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-52.15%
|
$3,933
$9.11 P/Share
|
|
Apr 18
2025
|
Paul Cohen |
BUY
Exercise of conversion of derivative security
|
Direct |
838
+50.0%
|
-
|
|
Apr 01
2025
|
Peter L. Fishman SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
857
-1.1%
|
$0
$0.65 P/Share
|
|
Apr 01
2025
|
Peter L. Fishman SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+3.12%
|
-
|
|
Mar 01
2025
|
Peter L. Fishman SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
891
-1.17%
|
$0
$0.63 P/Share
|
|
Mar 01
2025
|
Peter L. Fishman SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+3.31%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 505K shares |
|---|---|
| Open market or private purchase | 160K shares |
| Payment of exercise price or tax liability | 272K shares |
|---|